These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 1379663

  • 1. Prognostic value of serum beta 2-microglobulin in HIV infection.
    Krämer A, Goedert JJ, Wachter H, Fuchs D.
    Lancet; 1992 Aug 08; 340(8815):371. PubMed ID: 1379663
    [No Abstract] [Full Text] [Related]

  • 2. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
    Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV.
    N Engl J Med; 1990 Jan 18; 322(3):166-72. PubMed ID: 1967191
    [Abstract] [Full Text] [Related]

  • 3. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific.
    Krämer A, Biggar RJ, Hampl H, Friedman RM, Fuchs D, Wachter H, Goedert JJ.
    Am J Epidemiol; 1992 Jul 01; 136(1):71-80. PubMed ID: 1384311
    [Abstract] [Full Text] [Related]

  • 4. Surrogate markers for AIDS treatment.
    Jacobson M.
    Nurs Times; 1992 Jul 01; 87(22):49. PubMed ID: 1675013
    [No Abstract] [Full Text] [Related]

  • 5. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
    Dis Markers; 1990 Jul 01; 8(3):164-5. PubMed ID: 2125538
    [No Abstract] [Full Text] [Related]

  • 6. Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection.
    Lafeuillade A, Tamalet C, Pellegrino P, de Micco P, Vignoli C, Quilichini R.
    J Acquir Immune Defic Syndr (1988); 1994 Oct 01; 7(10):1028-33. PubMed ID: 7916049
    [Abstract] [Full Text] [Related]

  • 7. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR, Lizioli A, Arcidiacono I, Cantaluppi P, Filippi C, Sobatti D, Bedarida G, D'Agostino F, Cambie G, Nardella ML.
    Boll Ist Sieroter Milan; 1990 Jun 01; 69(2):423-30. PubMed ID: 1983798
    [Abstract] [Full Text] [Related]

  • 8. Immune activation markers and AIDS prognosis.
    Osmond DH, Shiboski S, Bacchetti P, Winger EE, Moss AR.
    AIDS; 1991 May 01; 5(5):505-11. PubMed ID: 1677808
    [Abstract] [Full Text] [Related]

  • 9. [Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS].
    Halota W, Jaruga B, Pawłowska M.
    Pol Merkur Lekarski; 2002 Aug 01; 13(74):126-8. PubMed ID: 12420343
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic and therapeutic technology assessment. Surrogate markers of progressive HIV disease.
    JAMA; 1992 Jun 03; 267(21):2948-52. PubMed ID: 1349928
    [No Abstract] [Full Text] [Related]

  • 11. Early markers of HIV infection and subclinical disease progression.
    Dolan MJ, Lucey DR, Hendrix CW, Melcher GP, Spencer GA, Boswell RN.
    Vaccine; 1993 Jun 03; 11(5):548-51. PubMed ID: 8098175
    [Abstract] [Full Text] [Related]

  • 12. [ Biological criteria for prediction of the clinical course leading to AIDS].
    Salmon D, Couroucé AM, Doinel C, Fine JM, Kaplan C, Lambin P, Lefrère JJ, Rouger P, Salmon C.
    Rev Fr Transfus Hemobiol; 1990 Dec 03; 33(6):407-14. PubMed ID: 1981002
    [No Abstract] [Full Text] [Related]

  • 13. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
    Siller L, Martin NL, Kostuchenko P, Beckett L, Rautonen J, Cheng SC, Wara DW.
    AIDS; 1993 Mar 03; 7(3):369-73. PubMed ID: 8097095
    [Abstract] [Full Text] [Related]

  • 14. Managing HIV. Part 4: Primary therapy. 4.3 The laboratory in managing HIV infection.
    Dwyer DE, Adelstein S, Cunningham AL, Merigan TC.
    Med J Aust; 1996 Mar 04; 164(5):301-3. PubMed ID: 8628167
    [Abstract] [Full Text] [Related]

  • 15. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
    Witt PL, Spear GT, Lindstrom MJ, Kessler HA, Borden EC, Phair J, Landay AL.
    AIDS; 1991 Mar 04; 5(3):289-93. PubMed ID: 2059368
    [Abstract] [Full Text] [Related]

  • 16. Beta-2-microglobulin, neopterin and monocyte Fc gamma receptors in opportunistic infections of HIV-positive patients.
    Dunne J, Feighery C, Whelan A.
    Br J Biomed Sci; 1996 Dec 04; 53(4):263-9. PubMed ID: 9069103
    [Abstract] [Full Text] [Related]

  • 17. Neopterin and beta-2 microglobulin levels in asymptomatic HIV infection: the predictive value of combining markers.
    Harrison NA, Skidmore SJ.
    J Med Virol; 1990 Oct 04; 32(2):128-33. PubMed ID: 2126281
    [Abstract] [Full Text] [Related]

  • 18. [Lymphocyte subpopulations, neopterin, and beta-2-microglobulin: relationship with clinical stage, risk of progression to AIDS and presence of active infection in HIV infection].
    Antón F, Labarga P, Pinilla J, Soto MJ, Leoz A, del Cura J, Borque L, Milazzo A.
    Enferm Infecc Microbiol Clin; 1993 Oct 04; 11(7):373-7. PubMed ID: 8104488
    [Abstract] [Full Text] [Related]

  • 19. Serum nitrite plus nitrate in infection with human immunodeficiency virus type-1.
    Zangerle R, Fuchs D, Reibnegger G, Werner-Felmayer G, Gallati H, Wachter H, Werner ER.
    Immunobiology; 1995 Jun 04; 193(1):59-70. PubMed ID: 7590863
    [Abstract] [Full Text] [Related]

  • 20. Markers of risk in HIV-1.
    Krämer A, Biggar RJ, Goedert JJ.
    N Engl J Med; 1990 Jun 28; 322(26):1886. PubMed ID: 1971915
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.